Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Is this about to take off? decent 200K buy today.
ANOTHER INTERVIEW -Flying Brands CEO, Nick Stevens with VOX Markets, also of the same period as the earlier posted with Proactive Investors.co.uk of July 2018.
Re: MAYO CLINIC & Biometrics Imaging [VOX interview & FDBU as above]
In essence, BioMetrics is "IN CLINICAL PRACTICE - MAYO CLINIC" Mentions a conference in Europe and Best Practice in Europe relating to Biometrics.
To listen to the audio interview, just put into the search engine Flying Brands plc VOX Markets and it is the top interview of July 2018.
Please check.
Prospectus - a lot of info in there even mentions Google HEalth might buy imaging companies as the sector consolidates
I need to watch that interview but we also need to hear from the company and its latest
P.S
The FBDU interview also mentioned that the placing [done] for StoneChecker & Imaging Biometrics - latter commercialisation efforts.
Link: www.proactiveinvestors.co.uk/LON:FBDU/FlyingBrandsLtd/
FBDU Video Interview: "StoneChecker still on track for FDA clearance and commercial roll-out of software." Proactive Investor.co.uk 23.7.18
In brief:
Flying Brands: Imaging Bio Metrics {2 products: IBO Euro & Rrd/Tex]
<>MAYO CLINIC,ARIZONA, USA {IBO Euro] - Mayo Clinic using IBO Euro in their Clinical WorkFlow. Useful for their surgeons re: brain tumour, putting needles into the tumour and not missing or around it. Shows where the brain tumour ends and inflammation starts. FDA clearance.
Note: Please check as there can be errors listening and trying to copy down the details.
DYOR.
few buyers about today. hahah!
we must have got revenue from this Michael Schmainda, CEO of IB said "We are delighted IB Software was chosen for this important multi-center trial. Our quantitative analysis resolves many inconsistencies that have inhibited routine and robust brain tumour assessment, and has the potential to cause a paradigm shift in how tumours are managed and treated. Moreover, IB Rad Tech streamlines the processing in a very consistent and cost-effective manner.".
People are forgetting, our brain AI product is already FDA cleared.
Yeah this share is craving for the news on fda approval
Hopefully i can get to ten grand pretty quickly from here.
Technology companies are exploring new avenues for their expertise in artificial intelligence (AI) can be put to better use. The world’s largest social networking company, Facebook Inc.has announced working on a research project related to medical imaging. The initiative is being jointly launched with a team of doctors in the radiology department of New York University's School of Medicine.
https://www.investopedia.com/news/facebook-ventures-medical-imaging-research/
Facebook engineers belonging to the Artificial Intelligence Research (FAIR) group plan to use neural networks for the innovative project called as fastMRI. Neural networks is a series of algorithms that seek to identify relationships in a data set via a process that mirrors the working of a human brain. The researchers will utilize around 3 million MRI images of the brain, liver and knees sourced from 10,000 different medical cases as available with the NYU School of Medicine. To ensure data security and necessary anonymity, all details of the involved patients are removed from the medical images. No data from Facebook social media profiles are being used.
Enters the world of medical imaging, breaking news
Thanks draft. Did not know this. Let’s see what happens within the next ten days
FDA Approval and licensing deal in North America in one RNS now that would be a carlsberg moment. Gla
Apparently FDA approval might not be far away now - 45 day delay mentioned on last youtube video - only 10 days left of that - interesting the point made was that Stone Checker were working with FDA to improve their submission, probably just a formality getting the FDA approval, then the sale and marketing can begin in earnest.
The Market will draft. It’s just that time is needed. This is one of those shares that needs time to build up. I remember mtr. That took forever to take off but when it did it went from .8 p to 6 p. I’m holding and waiting
just need the market to think AI and medtech is in vogue
There is no way this share is staying this low forever. I reckon when it wakes up it will bag easily. The main catalyst I strongly believe will be the fda approval
The medical imaging AI marketplace today is characterized by a dynamic and diversified competitive landscape, including major cloud computing vendors with partner-based imaging AI initiatives, computing acceleration vendors, cloud marketplace vendors, health IT vendors with a cloud partner ecosystem, core medical imaging and informatics vendors, major IT vendors, and more than 90 independent software vendors, according to Daher. The total number of medical imaging analysis AI start-ups has also grown from two in 2009 to 83 in 2017.
Money has also poured into this field. More than $1 billion -- led by $466.5 million invested in cardiovascular software developer HeartFlow -- has been raised in fewer than five years in the medical imaging AI market, Daher said. That total rises to as much as $6 billion if you include merger and acquisition activity and research and development from established market players, he added. Not many people targeting the Kidneys - Stone Checker onto something here.
Thanks draft. Interesting research that sheds some much-needed light on this share. Good weekend pal
The Future of Medical Imaging: AI, Cloud and Beyond
While medical sensors have played a key role in imaging in the last two decades, future approaches will revolve around computation and more-intensive compute power. Computation and AI make image gathering more efficient and shorten image acquisition times. In addition, the field will likely see more cloud-hosted medical imaging data.
“We're seeing a lot more movement toward cloud-hosted applications and technology using compute servers and more-intensive compute power that can be hosted remotely,” Harris says, adding that he would like to see AI algorithms cut down imagine processing time as well.
“We're looking at trying to replace some of that time-intensive work with a better segmentation that will allow us to produce the results in less time,” Harris says. “We have some cases that take us one to two hours, and if we can cut that time in half using advanced algorithms, that would be really great.”
In addition, AI will help radiologists spot images they would not be able to see with the human eye.
“There's a tremendous amount of data in the images that is currently lost because the human eye can't process it,” Harris says. “With the help of AI, there's a tremendous amount of information that could be gleaned quantitatively from that data and presented to the radiologist and referring physicians to help with diagnosis and treatment planning.”
With technologies like 3D medical imaging and artificial intelligence at doctors’ disposal, Powell thinks medical professionals can become “superhuman.”
“It's a brand-new tool in their toolbox,” she says of 3D imaging. “It has some really incredible superpowers.”
I think FBDU will add heart and breast imaging in my opinion so we have full suite of software. And looks like some big acquisitions in the imaging market at the moment. Marlborough medical imaging giant Hologic will acquire breast health imaging company Faxitron Bioptics for $85 million.
The acquisition of the Arizona-based digital radiography firm will bolster Hologic's breast health portfolio, specifically enabling Hologic to play a larger role in non-mastectomy breast surgery, which Hologic called an adjacent growth market of the company's interventional breast business.
Faxitron boasts a broad range of product categories, including digital specimen radiography, breast lesion localization and sentinel lymph node biopsy. Products in those categories are sold to breast surgeons and pathologists.
In an announcement of the acquisition, Hologic noted Faxitron's 3D product providing 360-degree images of excised lesions.
"Acquiring Faxitron is consistent with our capital deployment goals," said Steve MacMillan, Hologic's chairman, president and CEO. "This is a great tuck-in acquisition that leverages our existing strength in the breast health channel, while providing attractive growth and return on invested capital."
Faxitron, with revenues of $27 million last year, will be absorbed by the much larger Hologic, which on Tuesday reported third quarter revenues of $824 million and net income of $112.9 million, increases of 2.2 percent and 89.7 percent, respectively.
What is going on here again with the dips ??
we will get the same GE deals as feedback get as common directors. we really need feedback shareholders to get interested in this also.